Table 5.
Proportion of HBsAg, HBeAg, and HBV DNA alone and in tandem with ALT in predicting pathological conditions.
| Early HBeAg-positive cohort | ||||||||
|---|---|---|---|---|---|---|---|---|
| Variable * | N | ≤G1 and ≤S1, % (n) | ≤G1 and ≤S2, % (n) | ≥G2, % (n) | ≥G3, % (n) | ≥S2, % (n) | ≥S3, % (n) | ≥S4, % (n) |
| ALT < 40 | 164 | 50.6 (83) | 70.1 (115) | 26.2 (43) | 11.0 (18) | 47.6 (78) | 21.3 (35) | 11.6 (19) |
| HBsAg > 4.602 | 129 | 51.2 (66) | 70.5 (91) | 29.5 (38) | 10.1 (13) | 42.6 (55) | 9.3 (12) | 5.4 (7) |
| HBsAg > 4.602 plus ALT < 40 | 53 | 71.7 (38) | 94.3 (50) | 5.7 (3) | 1.9 (1) | 28.3 (15) | 1.9 (1) | 0.0 (0) |
| HBeAg > 3.114 | 119 | 56.3 (67) | 68.1 (81) | 30.3 (36) | 8.4 (10) | 35.3 (42) | 9.2 (11) | 3.4 (4) |
| HBeAg > 3.114 plus ALT < 40 | 45 | 80.0 (36) | 91.1 (41) | 8.9 (4) | 0.0 (0) | 17.8 (8) | 0.0 (0) | 0.0 (0) |
| Late HBeAg-positive cohort | ||||||||
| Variable * | N | ≤G1 and ≤S1, % (n) | ≤G1 and ≤S2, % (n) | ≥G2, % (n) | ≥G3, % (n) | ≥S2, % (n) | ≥S3, % (n) | ≥S4, % (n) |
| ALT < 40 | 174 | 48.3 (84) | 69.5 (121) | 27.0 (47) | 6.9 (12) | 49.4 (86) | 21.8 (38) | 13.8 (24) |
| HBsAg > 4.602 | 111 | 63.1 (70) | 79.3 (88) | 19.8 (22) | 3.6 (4) | 35.1 (39) | 7.2 (8) | 6.3 (7) |
| HBsAg > 4.602 plus ALT < 40 | 48 | 77.1 (37) | 91.7 (44) | 6.2 (3) | 2.1 (1) | 22.9 (11) | 4.2 (2) | 4.2 (2) |
| HBeAg ≤ 3.114 | 145 | 57.9 (84) | 73.8 (107) | 24.8 (36) | 2.1 (3) | 35.9 (52) | 6.9 (10) | 4.1 (6) |
| HBeAg ≤ 3.114 plus ALT < 40 | 44 | 75.0 (33) | 93.2 (41) | 4.5 (2) | 0.0 (0) | 22.7 (10) | 2.3 (1) | 2.3 (1) |
| Early HBeAg-negative cohort | ||||||||
| Variable | N | ≤G1 and ≤S1, % (n) | ≤G1 and ≤S2, % (n) | ≥G2, % (n) | ≥G3, % (n) | ≥S2, % (n) | ≥S3, % (n) | ≥S4, % (n) |
| ALT < 40 | 284 | 58.5 (166) | 77.1 (219) | 16.5 (47) | 7.4 (21) | 40.8 (116) | 18.3 (52) | 10.2 (29) |
| HBV DNA ≤ 3.301 | 209 | 59.8 (125) | 73.7 (154) | 19.6 (41) | 10.0 (21) | 38.8 (81) | 21.1 (44) | 13.4 (28) |
| HBV DNA ≤ 3.301 plus ALT < 40 | 165 | 65.5 (108) | 79.4 (131) | 13.3 (22) | 7.9 (13) | 33.9 (56) | 17.6 (29) | 10.3 (17) |
| Late HBeAg-negative cohort | ||||||||
| Variable * | N | ≤G1 and ≤S1, % (n) | ≤G1 and ≤S2, % (n) | ≥G2, % (n) | ≥G3, % (n) | ≥S2, % (n) | ≥S3, % (n) | ≥S4, % (n) |
| ALT < 40 | 441 | 63.9 (282) | 82.3 (363) | 14.1 (62) | 3.2 (14) | 35.4 (156) | 14.3 (63) | 7.7 (34) |
| HBV DNA ≤ 3.301 | 329 | 65.7 (216) | 81.5 (268) | 15.2 (50) | 4.3 (14) | 32.8 (108) | 14.3 (47) | 8.5 (28) |
| HBV DNA ≤ 3.301 plus ALT < 40 | 270 | 68.5 (185) | 86.3 (233) | 10.0 (27) | 2.2 (6) | 31.1 (84) | 11.5 (31) | 6.7 (18) |
ALT, alanine transferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus DNA; Gx (x = 0, 1, 2, 3 or 4), level of pathological grade; Sy (y = 0, 1, 2, 3 or 4), level of pathological stage.
* Units of measurement: ALT, IU/L; HBsAg, log10 IU/ml; HBeAg, log10 SCO; HBV DNA, log10 IU/ml.